D89.82
Autoimmune lymphoproliferative syndrome [ALPS]
Clinical Classification Guidelines
Medical Intelligence & Overview
Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare disorder of the immune system characterized by the abnormal production of lymphocytes, a type of white blood cell. The condition results from a problem with the way the body controls immune cell death, leading to enlarged lymph nodes, spleen, and immune system disturbances. ALPS is classified under the ICD-10 code D89.82 and typically manifests in childhood or adolescence. Although it is a chronic condition, early diagnosis and management can help control symptoms and prevent complications.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the FAS gene, which regulates programmed cell death in lymphocytes. Inheritance patterns are often autosomal dominant, meaning a single copy of the mutated gene can cause the disorder. In some cases, familial history suggests a hereditary component, although spontaneous mutations can also occur. Disruptions in the apoptosis pathway lead to the accumulation of lymphocytes, contributing to lymphadenopathy and splenomegaly.
Key Symptoms: Enlarged lymph nodes (lymphadenopathy), often painless and widespread Splenomegaly (enlargement of the spleen) Recurrent or persistent fevers Elevated levels of certain immune cells and autoantibodies Anemia, thrombocytopenia, or neutropenia, which can cause fatigue, easy bruising, and increased infections Autoimmune manifestations such as hemolytic anemia or immune thrombocytopenic purpura (ITP) Frequent infections due to immune dysregulation
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, laboratory tests, and genetic analysis, including: - Complete blood count (CBC) to assess blood cell levels. - Imaging studies like ultrasound or CT scans to evaluate lymph node and spleen size. - Blood tests to detect autoantibodies and markers of immune activity. - Genetic testing to identify mutations in the FAS gene. - Exclusion of other causes of lymphadenopathy and immune dysfunction. In some cases, specialized tests such as apoptosis assays may be used in research settings to confirm defective cell death processes.
Treatment Protocols: While there is no cure for ALPS, various treatment strategies aim to manage symptoms and prevent complications. These include: - Immunosuppressive medications such as corticosteroids to reduce lymphocyte proliferation and inflammation. - Use of drugs like sirolimus or everolimus to modulate immune responses. - Regular monitoring of blood counts and organ sizes. - Treatment of specific autoimmune issues, such as hemolytic anemia or ITP, with targeted therapies. - In severe cases, splenectomy may be considered; however, it carries risks outweighing benefits. - Supportive care, including infection prevention and management. Research is ongoing to develop targeted therapies that address the underlying genetic defects.
Clinical Advice & FAQs
Billing Guidance
Is D89.82 a billable ICD-10 code?
Yes, D89.82 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D89.82?
Clinical documentation must specify the nature of Autoimmune lymphoproliferative syndrome [ALPS] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference